Prevent Return of Stroke Study

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate if a peer-led stroke recurrence prevention intervention, versus usual care, will help reduce risk factors for recurrent strokes among adults in Harlem.

Clinical Trial Description

Twenty nine percent of the 700,000 strokes that occur yearly nationwide are among stroke survivors. Blacks, both nationally and among Harlem residents, have a twofold increase in recurrent strokes. Harlem Latinos have a threefold increase in risk relative to Whites.

Primary risk factors for recurrent stroke include hypertension, hyperlipidemia, and under use of anti-thrombotic agents. Controlling risk factors can be particularly challenging for low-income, minority populations who lack the resources needed to adhere to necessary therapies. In Harlem, 72% of adults studied six months post stroke did not have these three risk factors treated adequately.

We propose to determine if participation in a recurrent stroke prevention educational intervention, versus usual care, can activated stroke survivors to at reduce primary risk factors for recurrent strokes while providing an effective, low-cost, sustainable recurrent stroke prevention program in neighborhoods like Harlem, whose residents bear a disproportionate burden of suffering from strokes. Specifically, we propose:

1. Recruit 600 adults who sustained a stroke or transient ischemic attack (TIA) within the past five years by working with Harlem community leaders, local clinical sites including the Mount Sinai Medical Center and the Institute for Family Health, and the Visiting Nurse Service of New York;

2. To conduct a randomized, controlled trial to determine if participation in a peer-led stroke prevention program activates stroke and TIA survivors to improve their knowledge and self-management strategies and treatments related to stroke prevention; and

3. To rigorously compare the impact of the intervention with usual care (delayed intervention), on increasing the proportion of individuals with strokes and TIAs who are appropriately treated to reduce the risk of recurrent events, specifically through control of hypertension (blood pressure ≤ 140/90mmHg), hyperlipidemia (LDL cholesterol≤100 mg/dl) and use of anti-thrombotic medicines. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01027273
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	N/A
Start date	June 2009
Completion date	February 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00859885` - International PFO Consortium	N/A
Not yet recruiting	`NCT03605355` - Feasibility Study on the Medical and Economic Consequences of Outpatient Management of TIAs and Minor Strokes
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Completed	`NCT02905383` - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital	N/A
Completed	`NCT04078737` - Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II	Phase 3
Completed	`NCT02141932` - Pocket-size Cardiovascular Ultrasound in Stroke	N/A
Recruiting	`NCT01954329` - Markers in the Diagnosis of TIA	N/A
Completed	`NCT02011256` - Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack	N/A
Completed	`NCT01918891` - Center for Stroke Disparities Solution - Community Transitions Intervention	N/A
Recruiting	`NCT01526824` - Lovaza's Effect on Clopidogrel in a Neuro Population	Phase 0
Completed	`NCT01020851` - The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial	N/A
Completed	`NCT00597974` - Neurological Outcome With Carotid Artery Stenting	N/A
Completed	`NCT00211731` - Preventing Recurrent Stroke in Minority Populations	N/A
Active, not recruiting	`NCT03635749` - Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis	Phase 3
Completed	`NCT03153020` - Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône
Recruiting	`NCT04075500` - Optimal Detection of Atrial Fibrillation in TIA	N/A
Recruiting	`NCT06091319` - Florbetaben for Imaging of Vascular Amyloid
Completed	`NCT04604015` - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt	N/A
Completed	`NCT00885456` - Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT	Phase 2
Completed	`NCT05620966` - EEG to Diagnose TIA and Stroke

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.